Fusion Antibodies News

Fusion Antibodies announce in-licensing of Am2r Antibody

Fusion Antibodies Ltd are pleased to announce the in-licensing of the anti-AM2R monoclonal antibody from Medella Therapeutics, to use our CDRx™ humanization technology to develop it as a novel 1st in class therapy for serious cancers with…

Fusion Antibodies and Mab Discovery announce project collaboration

Fusion Antibodies, a UK-based contract research organisation and MAB Discovery, a unique antibody discovery company, have announced their intention to enter into a research and licence agreement in the field of monoclonal antibodies. Within…

Fusion Antibodies to double workforce with help from Invest NI

Fusion Antibodies is set to double its workforce as part of an investment supported by Invest NI. Its planned expansion, which also includes doubling revenues with the next three years, will create 15 jobs. Invest NI has provided…

Fusion Antibodies conferences and events 2016

Fusion Antibodies will be attending the following events in 2016: BioShowcase USA San Francisco January 10th Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and…

Fusion Antibodies receive award

Fusion Antibodies are pleased to announce that we have been awarded a Crescent Capital Green Bar Award. The award recognises the company’s achievement of five profitable quarters of growth in succession. The award was presented to…

February discounts with Fusion Antibodies

Fusion Antibodies have some fantastic offers for you throughout February! For all new customers, we are offering 25% off the in silico design stage of our best in market Ab Humanization services*.For all existing…

We’re Hiring!

Fusion Antibodies are currently recruiting for a scientific position. Apply today at jobs@fusionantibodies.com Fusion Antibodies are currently recruiting for a scientific position. Please see more details below or email jobs@fusionantibodies.com Scientist…

Why is Antibody Humanization still important in the 21st century?

Monoclonal antibodies, or mAbs, have become a crucial tool and are used for both diagnostic and medical applications. This article will explain the importance of mAbs and antibody humanization techniques involved. If you are interested…

Merry Christmas and Happy New Year!

We would like to take this opportunity to wish you all a Merry Christmas and a Happy New Year! Dear Fusion Antibodies Clients, It has been a fantastic year for Fusion Antibodies with our humanization service in particular welcoming…

2015 Bio-Europe conference

Fusion Antibodies are happy to announce we will be attending BIO-Europe which is to be held from the 2nd to the 4th of November 2015. BIO-Europe is the largest partnering conference in Europe and attracts thousands of companies and attendees…

Fusion Antibodies to attend Hah 2015

Fusion Antibodies are pleased to announce that we will be attending the 2015 Human Antibodies and Hybridomas Conference, to be held 28-30th of October at the University of Lausanne, Switzerland. Conference activities will include keynote…

Fusion Antibodies and Clarity Pharmaceuticals sign agreement for Fsn0503 anti-cathepsin antibody

Fusion Antibodies Ltd, an antibody drug and cell line development CRO focused on the treatment of serious disease, has signed an exclusive licensing agreement with Clarity Pharmaceuticals Ltd. (Sydney, Australia) to further develop Fusion’s…